The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma-Reference-Cited by-同舟云学术

The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma

Published:2001-03 Issue:3 Volume:112 Page:814-819
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Davies Faith E.,Forsyth Peter D.,Rawstron Andrew C.,Owen Roger G.,Pratt Guy,Evans Paul A. S.,Richards Stephen J.,Drayson Mark,Smith Graeme M.,Selby Peter J.,Child J. Anthony,Morgan Gareth J.

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-2141.2001.02530.x/fullpdf

Reference25 articles.

1. Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry;Algere;Bone Marrow Transplantation,1998

2. Intensive combined therapy for previously untreated aggressive myeloma;Attal;Blood,1992

3. A prospective randomised trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma;Attal;New England Journal of Medicine,1996

4. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma;Barlogie;Blood,1997

5. Total therapy with tandem transplants for newly diagnosed multiple myeloma;Barlogie;Blood,1999

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Kidney Transplant Outcomes of Patients With Multiple Myeloma;Kidney International Reports;2022-04

2. Pitfalls in Assessing Measurable Residual Disease in Plasma Cell Myeloma: a Comparison between Common Laboratory Tests;Clinical Laboratory;2022

3. Tumor Microenvironment of Lymphomas and Plasma Cell Neoplasms: Broad Overview and Impact on Evaluation for Immune Based Therapies;Frontiers in Oncology;2021-12-08

4. Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches;Frontiers in Oncology;2020-05-27

5. MRD Testing in Multiple Myeloma: From a Surrogate Marker of Clinical Outcomes to an Every-Day Clinical Tool;Seminars in Hematology;2018-01